Nike Posts Q4 Earnings Above Expectations Amid China Sales Decline Nike Inc. reported fiscal fourth-quarter earnings of 20 cents per share, exceeding analysts’ expectations of 13 cents, according to a …
Tag:
Pfizer Inc
-
-
Pfizer Inc. (NYSE: PFE) is restructuring its business model following the decline of revenue from COVID-19 vaccines, focusing on long-term growth through expanded drug pipelines, strategic acquisitions, and cost efficiencies, …
-
Pharmaceutical manufacturers are rapidly shifting their obesity drug pipelines toward oral medications and infrequent dosing schedules to capture a larger share of the global weight-loss market. While Eli Lilly and …
-
Innovent Biologics and Pfizer Announce $10.5 Billion Oncology Partnership Shares of Hong Kong-listed Innovent Biologics surged on Friday following the announcement of a massive global licensing and collaboration agreement with …
-
AI Infrastructure Watch: Palantir and AMD Set to Define the Next Earnings Cycle The financial markets are bracing for a pivotal week as two of the most influential names in …
-
Pfizer to Pursue Lyme Disease Vaccine Approval Despite Late-Stage Trial Setback Pfizer announced on Monday it will seek regulatory approval for its investigational Lyme disease vaccine, despite the fact that …
-
FDA Vaccine Chief Dr. Vinay Prasad to Depart in April Dr. Vinay Prasad, the director of the Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research, will abandon …
-
Declining Birth Rates in Ukraine and Russia: A Looming Demographic Crisis Four years of war between Russia and Ukraine are beginning to capture their toll on the countries’ demographics, as …
-
Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker fights to regain investor confidence in its …
-
Zealand Pharma Outlines Ambitious 5-Year Obesity Drug Strategy Amidst Growing Competition Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for it’s anti-obesity portfolio …
Newer Posts